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Recent data have linked hypoxia, a classic feature of the tumor microenvironment, to the function of specific microRNAs
(miRNAs); however, whether hypoxia affects other types of noncoding transcripts is currently unknown. Starting from a genome-
wide expression profiling, we demonstrate for the first time a functional link between oxygen deprivation and the modulation of
long noncoding transcripts from ultraconserved regions, termed transcribed-ultraconserved regions (T-UCRs). Interestingly,
several hypoxia-upregulated T-UCRs, henceforth named ‘hypoxia-induced noncoding ultraconserved transcripts’ (HINCUTs),
are also overexpressed in clinical samples from colon cancer patients. We show that these T-UCRs are predominantly nuclear
and that the hypoxia-inducible factor (HIF) is at least partly responsible for the induction of several members of this group.
One specific HINCUT, uc.475 (or HINCUT-1) is part of a retained intron of the host protein-coding gene, O-linked
N-acetylglucosamine transferase, which is overexpressed in epithelial cancer types. Consistent with the hypothesis that T-UCRs
have important function in tumor formation, HINCUT-1 supports cell proliferation specifically under hypoxic conditions and may
be critical for optimal O-GlcNAcylation of proteins when oxygen tension is limiting. Our data gives a first glimpse of a novel
functional hypoxic network comprising protein-coding transcripts and noncoding RNAs (ncRNAs) from the T-UCRs category.
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Hypoxia is one of the classic features of the neoplastic
microenvironment and is causally associated with resistance
to conventional anticancer therapy.1 Under hypoxic condi-
tions, cells undergo a complex adaptive process involving
genes regulating angiogenesis, cell invasion, metabolism and
survival pathways. Novel insights into the pathways regulated
by low oxygen concentration have shown that in addition to
protein-encoding genes, the noncoding transcriptome is also
affected by hypoxia. We and others previously reported that
hypoxia regulates specific microRNAs (miRNAs), which in
turn regulate signals of relevance for tumor biology,2–5
including angiogenesis, cell cycle, DNA repair and energy
metabolism.5,6
During the past few years, it has become clear that long
noncoding RNAs (ncRNAs) (4200 bp in length) also partici-
pate in complex genetic events in eukaryotes.7 One intriguing
family of long ncRNAs8 is transcribed from regions that exhibit
extremely high conservation between the orthologous regions
of human, rat and mouse genomes,9,10 hence the term
‘transcribed-ultraconserved regions’ (T-UCRs) or ultracon-
served genes.8 Their striking evolutionary retention strongly
suggests profound biological roles in a wide variety of
physiologic responses. Recent studies have identified altera-
tions in T-UCR-expression patterns that are associated with
specific tumor phenotypes, pointing towards a mechanistic
involvement of T-UCRs in cancer development. In particular,
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alterations in T-UCR expression have been described in adult
chronic lymphocytic leukemia, colorectal cancer (CRC),8
hepatocellular carcinomas8,11 and neuroblastomas.12,13
In the human genome, T-UCRs are often found to overlap
with exons of genes involved in RNA splicing or are located
within host gene introns or in close proximity to genes that are
involved in transcription and development regulation.9,14
Whereas ultraconserved sequences appear to act
as tissue-specific regulators of gene expression during
development,7,9,15 very little, if anything, is currently under-
stood about the mechanisms underlying the cancer-asso-
ciated profile alterations of the T-UCR. To address this
limitation, we hypothesized that decreased oxygenation
contributes to the deregulation of specific T-UCRs in cancer,
pursuing a similar rationale to our original work on hypoxia-
regulated miRNAs.2 We initiated the search by exposing
several cancer cell lines to low oxygen followed by quantifica-
tion of changes in T-UCR expression versus normoxic
controls using a genome-wide microarray profiling.
Subsequently, we interrogated the contribution of hypoxia-
inducible factor (HIF) activity to the upregulation of a set of
hypoxia-induced noncoding ultraconserved transcripts
(HINCUTs). Finally, the leading candidate of this group was
functionally dissected in detail.
Results
T-UCR-expression changes under hypoxic conditions
in malignant cells. We re-interrogated our previous
microarray data (Array Expression accession: E-TABM-184)
obtained from CRC samples (78 CRCs compared
with 21 normal colonic mucosas)8 to identify T-UCRs over-
expressed in CRC that could be potentially induced
by hypoxia (for a detailed workflow, see Figure 1a and
Supplementary Figure 1). The same type of microarrays
was used for the discovery of hypoxia-induced miRNAs.2
We identified 61 T-UCRs that had a significantly (P-value
o0.05 Welch t-test with Benjamini–Hochberg correction)
altered expression in CRC when compared with normal colon
tissue (59 overexpressed and two with lower expression).
Twenty-seven T-UCRs were upregulated compared with
normal colonic mucosa at a more stringent P-value o0.005,
and further analyzed (Supplementary Table 1).
In order to validate the microarray data, we exposed two
cancer cell lines (HCT-116 CRC and MCF-7 breast cancer
cells) to 1% oxygen or 500mM DMOG (dimethyloxalylglycine)
– a widely used hypoxia mimetic – for 24 and 48 h and
measured T-UCR expressions using quantitative reverse
transcriptase PCR (RT-qPCR). Comparisons were performed
with normoxic controls (21% oxygen) or dimethyl sulfoxide
(0.5% DMSO). We identified a set of T-UCRs (uc.63, uc.73,
uc.106, uc.134 and uc.475) that was induced more than
two-fold (P-valueo0.05 by Student’s t-test) after 48 h both of
hypoxia and DMOG exposures (Figure 1b and Table 1).
All of these transcripts were predominantly present in the
nucleus, as identified by nuclear and cytoplasmic
fractionation experiments (Supplementary Figure 2). Robust
activation of hypoxia signaling was confirmed by HIF-1a
(or HIF-2a) protein overexpression (Figures 1b and c),
carbonic anhydrase IX (CA9) (data not shown) and miR-210
(Supplementary Figure 3) gene expression levels, which are
both well-established coding and noncoding HIF targets,
respectively.2 Henceforth, these T-UCRs will be referred to as
HINCUTs; their functional dissection under low-oxygen
conditions is described below.
Evidence for HIF as HINCUT’s regulator. The effect of
DMOG on the expression of HINCUTs suggests a central
role for HIFs as an upstream regulator. To further address
the role of HIF, we used the renal cell carcinoma (RCC)
cell line 786-O, which exhibits homozygous inactivation of
the von Hippel–Lindau tumor suppressor gene (VHL), the
well-established E3 ubiquitin ligase for all HIF family
members. 786-O cells exhibit constitutive activation of the
HIF pathway.16 We hypothesized that HIF-2a-induced
T-UCR expression would have a similar pattern. To this
end, when we compared normoxic 786-O cells expressing an
empty vector with cells expressing wild-type VHL to restore
the defects, and consistent with being bona fide HIF-2a
targets, all HINCUTs were upregulated at least 1.5-fold in the
VHL-deficient cell line (VHL ) compared with the VHL-
restored (VHLþ ) cells (Figure 1c). Furthermore, time course
experiments in hypoxic models revealed that uc.475 was the
most consistently induced (Supplementary Figure 4).
As no T-UCR promoter has been characterized to date, we
performed an in silico search for HIF-binding sites within
the 15-kb genomic region surrounding HINCUTs. For uc.63,
uc.73, uc.134 and uc.475, we found multiple putative HIF-
binding sites per UCR (Supplementary Table 2). Then
T-UCRs with yet unknown functional role and more than one
binding sites identified were also included in these studies. In
the uc.63 promoter region, we identified the following three
candidate HIF-binding sites: Q3_uc.63A 50-GGCAACGTG
CATG-30 (63A.1), Q3_uc.63A 50-GAGTGCGTGCTCCT-30
(63A.2) and Q6_uc.63A 50-CGCGTGTGC-30 (63A.3), where
as for uc.475 the following three candidate sites were found:
Q3_uc.475 50-GCTCGCATGCGCGG-30 (475.1) and two in
close proximity with each other, Q5_uc.475 50-CACACGT
GCGCG-30 and Q6_uc.475 50-CACGTGCGC-30 (475.2)
(Figure 2a).
To further substantiate the role of HIF in the regulation
of uc.475 and uc.63, we performed chromatin-immuno-
precipitation assay (ChIP) of HIF-1a in MCF-7 cells under
normoxic conditions or following treatment with the hypoxia
mimetic, DMOG. We confirmed direct recruitment of
endogenous HIF-1a at the promoters of uc.63 (data not shown)
and uc.475, which was more evident during hypoxic conditions
(Figure 2a; genomic regions from The University of California,
Santa Cruz (UCSC) Genome Browser (http://genome.ucsc.
edu/)17 NCBI36/hg18). For each ChIP reaction, we used the
promoter ofCA9, awell-characterizedHIF target, as the positive
control and hemoglobin beta (HBB) as the negative control.
We further confirmed the transcriptional activation of uc.475
by hypoxia and HIF-1a using promoter fragments subcloned
into the pGL4-10 (luc2) basic expression vector. These
constructs were co-expressed with the pRL-TK (Renilla)
control vector and constitutively active HIF-1a constructs
(pcDNA 3.1-HIF-1a P/A (proline/alanine mutant) and pcDNA
3.1-HIF-1a 3M (proline/alanine/asparagine mutant)18 in two
CRC cell lines, HCT-116 and HT-29 cells (Figures 2b and c).
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We found that hypoxia and the active HIF-1as induced an
increase (up to five-fold) in luciferase activity (Figure 2b),
which was correlated with the uc.475 expression in these cells
(Supplementary Figure 5). In contrast, luciferase activity of the
mutant clones that lack HIF-1a-binding sites (PT1 and PT2)
was significantly reduced (Figure 2c) (P-value o0.005),
suggesting that the two predicted binding sites are functional
HIF-recognition sites that mediate hypoxia effects on uc.475
transcription.
Biological effects of uc.475 downregulation. To deter-
mine the biological significance of HINCUTs, we performed
knockdown experiments for uc.63 and uc.475 using custom-
designed siRNAs and found that these effected cell
proliferation using the general strategy described initially for
uc.73.8 siRNA-specific oligonucleotides for HINCUTs were
designed after evaluating by strand-specific RT-qPCR if the
sense or antisense transcript was transcribed at higher levels
(Supplementary Figures 5 and 6). No major biological effect
Figure 1 T-UCR-expression induction by hypoxia. (a) Experiment flowchart. (b) RT-qPCR confirmation of T-UCR-expression induction after 48 h under hypoxic conditions
in HCT-116 colon cancer cells and hypoxia-simulation conditions by DMOG in the MCF-7 breast cancer cell line. Expression was normalized versus normal conditions
(normoxia in HCT-116 and DMSO in MCF-7). Bars indicate the standard deviation from two sample duplicates. Western blot assay performed with HIF-1a-specific antibodies.
(c) T-UCR induction measured using RT-qPCR in the VHL-deficient (VHL ) cell line was compared with that in the VHL-proficient (VHLþ ) 786-O cell line under normoxic
conditions. Western blot analysis was performed using HIF-2a-specific antibodies. *Po0.05; **Po0.01; ***Po0.001
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on the dynamics of COLO-205 culture was identified
for uc.63 (Supplementary Figure 7) and henceforth,
we focused our efforts on uc.475. Notably, the primary
uc.475 transcript has the same orientation as its host gene,
O-linked N-acetylglucosamine (GlcNAc) transferase (OGT)
(Supplementary Figure 6). The effect of uc.475 downregula-
tion on cell survival was tested in HT-29 cells under hypoxic
and normoxic conditions. These cells were chosen based
on their high endogenous uc.475 expression level
(Supplementary Figure 5). We employed a custom-designed
pool of siRNAs to knockdown uc.475; each of the three
siRNAs tested to be efficient reduced the basal expression of
uc.475 by more than 65% as confirmed by RT-qPCR
(Supplementary Figures 7 and 8 and Supplementary
Table 3).
Under normoxic conditions, downregulation of uc.475 had
no significant impact on the total cell number versus control
(siRNA-NEG) cells for up to 120 h (Figure 3a, left). In contrast,
under hypoxic conditions (1% O2), uc.475 knockdown
significantly decreased cell proliferation (Figure 3a, right).
This effect was not the result of increased apoptosis, as poly
ADP-ribose polymerase, a critical component of programmed
cell death, remained uncleaved (data not shown). Instead,
through the analysis of the cell cycle, using fluorescence-
activated cell sorting (FACS), we observed that uc.475
knockdown under hypoxic condition enriched the G2/M
fraction more than two-fold at 72 and 96 h (from 10.3 and
8.2% with the negative control to 21.7 and 18.8% with siRNA,
respectively), suggesting a G2/M blockade. No similar
consistent variations in the percentage of cells in the various
phases of the cell cycle under normoxic conditions were
identified (Figure 3b and Supplementary Figure 9). Cell cycle
distribution was also checked after treatment with siRNA
against OGT (Supplementary Table 3 and Supplementary
Figure 8) under normoxia and hypoxia, and only minimal
effects on cell cycle progression were observed
(Supplementary Figure 9b). To exclude the possibility that
siRNA against uc.475 downregulates pre-mRNA of OGT and
leads to a phenotypic effect, we designed another siRNA
targeting another intron of OGT. We selected intron 12 to
knockdown the pre-mRNA, as this siRNA exhibited the
highest efficiency among several siRNAs we have designed.
As a result, although OGT protein expression was moderately
downregulated by OGT-intron 12 knockdown, more
significant reduction was observed with uc.475 knockdown
(Figure 3c), and no proliferation inhibition or altered cell cycle
distribution was observed after the knockdown of OGT-intron
12 (Supplementary Figure 11). These results indicate that the
alteration of OGT expression and proliferation inhibition by
uc.475 knockdown is a distinct effect of the OGT pre-mRNA
knockdown.
OGT locus: a mix of OGT and HINCUT-1 transcripts. As
mentioned previously, and in line with earlier reports,19–21 the
uc.475 sequence (396 bp in length) is found inside the
fourth intron of the OGT gene (UCSC Genome Browser;
GRCh/hg19, Figure 4a). OGT has two known isoforms
(OGT1 of 5497bp and OGT2 of 5467bp) because of a
variant splice site, which is known to encode proteins of 1046
or 1036 amino acids (116 and 103 kDa), respectively, and
that catalyze polypeptide glycosylation by the addition of
N-acetylglucosamine
(O-GlcNAc) to serine and threonine residues (O-GlcNAcylation)
on many nuclear and cytosolic proteins.19 Recently, this
modification was proposed to be a new link between glucose
metabolism and cancer growth and invasion in breast,22 colon
and lung cancer types.23 In addition, OGT was found to
be highly expressed in prostate cancer compared with the
normal epithelium.24 Taking into account the link between
OGT and cancer, we hypothesized that this, at least in part,
could be explained by the associated uc.475 transcript with a
potential role as the regulator of its host gene expression
during hypoxia.
By using a multiple-primer amplifications approach, we
cloned a transcript ofB2.7 kb that included the uc.475 region
but excluded the flanking OGT exons (for details see
Supplementary Figure 12). In contrast, amplification levels
were much lower when primers in the ‘flanking’ OGT exons
(Exons 4 and 5) and intron region containing uc.475 were
used in combination; theOGT and uc.475 transcriptswere 2–10
times more abundant than the amplicons obtained with the
mixed combinations of primers between flanking sequences
of uc.475 and exons of OGT (Figure 4b). These data support
two possibilities: (a) the existence of an OGT-independent
transcript that contains the fourth intron or (b) the existence of
a primary transcript that contains both OGT and uc.475 but is
further spliced into two transcripts, one noncoding (the intronic
uc.475) and one coding (the OGT isoforms).
Table 1 Genomic information for the five HINCUTs identified in the present study
T-UCR
Genomic











uc.475þ Xq13.1 OGT (O-linked N-acetylglucosamine
(GlcNAc) transferase)
Intron 2 S 397 2.02 2.30
uc.63þ /þA 2p15 XPO1 (Exportin 1) Intron 3 AS 278 2.51 2.11
uc.73þA 2q22.3 GTDC1 (Glycosyltransferase-like domain
containing 1)
Intron 6 AS 201 2.56 2.05
uc.106þ 2q31.1 OLA1 (Obg-like ATPase 1) Intron 4 AS 206 2.07 2.51
uc.134þA 3q25.32 RSRC1 (Arginine/serine-rich coiled-coil 1) Intron 7 S 211 2.01 2.28
Abbreviations: DMOG, dimethyloxalylglycine; DMSO, dimethyl sulfoxide; HINCUT, Hypoxia-induced noncoding ultraconserved transcripts
Location data are according to the UCSC Genome Browser (assembly GRCh37/hg19). Host gene names are according to the HUGO nomenclature. AS or þA,
antisense; S or þ , sense; nt, nucleotide; we used the same name for the T-UCR as for the array probes found in E-TABM-184
aHost gene orientation is reported versus HINCUT orientation considered as reference
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To further substantiate the tight link between OGT and
uc.475, we performed experiments under stress conditions
for which OGT function is relevant.25 As OGT-mediated
O-GlcNAcylation is proportional to substrate (glucose)
availability,26 we performed experiments under glucose- as
well as oxygen-deprivation conditions (OGD experiments) –
two tightly associated characteristics of the tumor micro-
environment. In HT-29 cells, the expression levels of uc.475
Figure 2 Confirmation of a direct association between HIF and T-UCR using ChIP and luciferase assay. (a) Direct recruitment of HIF on T-UCR-expression induction in
hypoxia-simulated conditions by DMOG in the MCF-7 breast cancer cell line. We confirmed a direct connection between HIF and T-UCR (uc.475) using ChIP method with
HIF-1a antibodies or an IgG control. To enrich genomic fragments that contain hypoxia-response elements (HIF-interacting sites), we amplified the regions represented on the
genome graphic using specific primers for pointed locations. The ChIP figures are inverted for a better view of expression induction. NC, negative control; HBB, hemoglobin
globin beta, which is supposed to be transcriptional inactive; and carbonic anhydrase IX (CA9), which was used as a positive control in the ChIP experiment. (b) The direct
effect of HIF on the uc.475 promoter reporter construct was confirmed by using luciferase assay and was shown as an effect of exogenous pcDNA 3.1-HIF-1a vector
constructs (HIF-1a P/A and HIF-1a 3M) on cloned promoter activity. A stronger effect was detected by using luciferase assay normalized using empty pcDNA 3.1 vector. The
error bars represent the standard deviation from two independent experiments, each performed in triplicate and measured in duplicate with a luciferase assay. (c) Luciferase
activity in HCT-116 and HT-29 cells was measured after transfection with truncated promoter reporter constructs (PT1 and PT2) with a complete deletion of the HIF-1a-binding
sites that were present in the originally designed uc.475 promoter reporter construct (WT). Filled circles show the position of the HIF-1a-predicted binding site. ***P-value
o0.001 compared with luciferase activity of an empty vector; WT, wild type; PT1, truncated promoter 1; PT2, truncated promoter 2
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and OGT mRNA significantly increased during 12 and 24 h of
normoxia in glucose-free media. After 48-h exposure under
these conditions, the expression of both decreased dramati-
cally to the same or lower level observed under hypoxia in the
presence or absence of glucose (Figure 4c). These data show
that the responses of uc.475 and OGT mRNA expression to
oxygen and glucose deprivation are similar.
In parallel, we attempted to visualize the sizes of the
transcripts from this locus by using Northern blot analysis.
This would allow us to determine whether uc.475 exists as an
independent transcript, or only part of a hybrid transcript with
OGT, or as both. We used RNA isolated from MCF-7 cells
after exposure to hypoxia or normoxia for 24 h. Using a
probe specific to uc.475, we identified two transcripts (B8
andB9.5 kb) with higher expression under hypoxia in MCF-7
cells, whereas theOGT-coding region transcripts (4.2 kb long)
had barely detectable signal (Figure 5, left). Hybridization with
an OGT-specific probe detected two transcripts (1.7 and
4.2 kb) with similar intensity under both normoxia and hypoxia
conditions (Figure 5, right). Therefore, we believe that uc.475
is the part of a larger OGT primary transcript, which retains
intron 4 and which is expressed in a hypoxia-dependent
manner.
When we screened for potential open reading frames
(ORF) in the ‘retained intron’, we detected no ORF4100bp.
The 9-kb transcript was not predicted to encode for either of
the two OGT isoforms, as the predicted ORF corresponds to
665 amino acids, potentially representing the smaller 78-kDa
version of the OGT reported recently19,20,27 (Supplementary
Figure 13). In addition, we have searched for miRNAs and
other putative ncRNAs in the uc.475 region using the UCSC
database, in which current integrated RNA deep-sequencing
experiment data (RNA-seq and miRNA-seq) are available,
and found no annotated miRNAs or other ncRNAs to be
located within the uc.475 region.
Uc.475 inhibition has an impact on OGT expression and
function. We first investigated whether OGT expression
at RNA and protein levels was affected by uc.475 knockdown
in HT-29 cells. Expression of OGT mRNA levels was
decreased by knocking down uc.475 (Figure 6a), as well as
OGT protein levels, which was more evident in hypoxia
(Supplementary Figure 10). Silencing OGT with siRNAs
(siRNA-OGT) resulted in decreased levels of uc.475 and
OGT mRNAs (Figure 6b) and OGT protein expression
(Figure 6c). Interestingly, and contrary to the mRNA, the
OGT protein level does not increase in hypoxia, as
evidenced by measurements performed in three different
cell lines – HCT-116 colon cancer, MCF-7 breast cancer and
U-87 glioblastoma cells (Supplementary Figure 14).
To provide functional support for the impact of uc.475
downregulation on OGT function, we quantitated the
O-GlcNAcylation rate following siRNA-mediated knockdown
of the transcript containing the ultraconserved sequence
(Supplementary Figure 15). This was performed in HT-29
cells treated with PUGNAc (1,5-hydroximolactone), an inhi-
bitor of the N-acetylhexosaminidases (OGA or MGEA5),
in order to prevent the removal of O-GlcNAc from proteins.28
Downregulation of uc.475 led to a significant decrease in the
global O-GlcNAcylation rate, an effect similar to treatment
with OGT-siRNA (Figure 6d), whereas the inhibition of OGT
protein and global O-GlcNAcylation was relatively modest
after treatment with siRNA against OGT-intron 12, which
targets OGT pre-mRNA.
The enhancer-like function of the DNA region containing
uc.475 ncRNA. It has been reported that ultraconserved
regions can act as developmental enhancers, so we
determined whether, in addition to having a transcriptional
activity, the uc.475 could also have an enhancer function.29
We used sequence-transcription stimulation by an adjacent
heterologous promoter region as previously described.30
The 2.7-kb long region ( 1 kb upstream and þ 1.3 kb
downstream of uc.475) (Supplementary Figure 12) was
subcloned into the pGL3-TK vector (Figure 7a). This cloned
insert revealed 2-3 fold luciferase activity enhancement,
under both normoxia and hypoxia, in U-87 cells (Figure 7b).
These findings demonstrate that the uc.475 DNA region also
has an enhancer activity both under hypoxic and normoxic
conditions.
Discussion
We aimed to investigate whether hypoxia induces the
expression of noncoding ultraconserved transcripts in a
similar manner to the conventional hypoxia-regulated genes
or more recently studied miRNAs. To this end, we employed a
strategy that integrates tumor data with a microarray-based
screen.2 We identified in multiple cell types the following
hypoxia-induced, noncoding ultraconserved transcripts:
uc.63, uc.73, uc.106, uc.134, and uc.475, and termed these
HINCUTs. Similar to the earlier work on miRNAs,2 we are
providing evidence that HIF has a critical role for their hypoxic
regulation, based on induction with chemical inactivators of
the HIF prolyl hydroxylases, effect of the VHL tumor-
suppressor inactivation and effect of exogenous HIF-1as on
luciferase reporters containing fragments from the candidate
promoters of HINCUTs. We identified HIF-1a-binding sites
upstream of uc.475. This region in fact overlaps theOGT gene
promoter region; therefore, the transcriptional control of
uc.475 is not considered to be completely distinct from OGT
transcription. Our in silico prediction detects no putative
binding site for HIF-1a very close to OGT intron 4, where
uc.475 is located. Recent reports have demonstrated
that many intronic miRNAs possess their own promoter,
which is independent of the host gene transcription.31
Figure 3 Uc.475 biological significance under normoxia and hypoxia. (a) The effect of siRNA-targeting uc.475 on cell proliferation was determined under normoxic (left)
and hypoxic (right) conditions by using a pool of three siRNAs against uc.475 (siRNA-uc.475). Three independent experiments were performed, and as control scrambled
siRNA sequence, siRNA-NEG, was used. (b) FACS analysis was performed 72 and 96 h post transfection with either siRNA-uc.475 or siRNA-NEG in normoxia (left) and
hypoxia (right). (c) Western blot analysis to detect differences of uc.475 host gene (OGT) protein expression levels. Hypoxic conditions were confirmed by CA9 induction.
Protein-specific bands were normalized to beta-actin. siRNA against OGT pre-mRNA was designed to target OGT-intron 12. *P-valueo0.05, **P-valueo0.01, ***P-value
o0.001
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Figure 4 Transcripts produced at the uc.475 genomic locus in an environment deprived of oxygen and/or glucose. (a) The genomic region of OGT from the
UCSC Genomic Browser, GRCh37/hg19 with the known transcripts of OGT isoforms 1 and 2. The rounded rectangle represents region containing uc.475. Northern blot-probe
locations are indicated. The intron 4 region where uc.475 is located is zoomed in for better view of region of conservation in mammals. (b) RT-qPCR data showing that the
uc.475 noncoding transcript and the coding OGT transcript are expressed at similar levels, whereas the ‘hybrid’ amplicons between the intron and the two adjacent
exons are barely expressed. (c) Glucose- and oxygen-deprivation effects on mRNA expression level of uc.475 and OGT. CA9 mRNA expression was analyzed as a hypoxia-
induced gene
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Further investigation is required to reveal whether there is an
additional transcriptional factor-binding site closer to the
uc.475 region.
Our data suggest that uc.475 is part of a primary (potentially
retained intron) transcript that also includes the coding
sequences of its ‘host gene’ OGT. The role of OGT is
to catalyze the addition of O-GlcNAc on proteins, which are
involved in transcription, cellular signaling pathways and
processes, and the cell cycle.27,32 OGT was also recently
reported to be overexpressed in breast cancer and primary
and metastatic prostate cancer,22,24 further supporting OGT
as a therapeutic target in solid malignancies.
Our results may expand the understanding of the complex-
ity of the OGT genomic locus, as it reveals the presence of a
noncoding ultraconserved sequence, part of a retained intron,
at the core of a hybrid nuclear transcript. We provide evidence
that the OGT locus generates multiple coding and noncoding
transcripts. The retained intron that contains uc.475 does not
possess a coding ORF but does include a second start codon
(ATG) or it could be part of a long 50-untranslated region
(3.27 kb).21
We also noticed a contrast between the hypoxia-inducible
nature of OGT/uc.475 at RNA and protein levels. Indeed,
measurements in multiple cell lines indicate that OGT is either
unchanged (Supplementary Figure 14) or even decreased
during oxygen deprivation (data not shown). This is likely part
of the wide translational suppression consistently reported
under hypoxia. Higher transcript levels may serve to
compensate this decrease, and it is entirely conceivable that
in the absence of mRNA induction the level of O-GlcNAcyla-
tion would be compromised below the level compatible with
survival.
What is therefore the role of uc.475-containing noncoding
region in the context of OGT-hypoxic regulation?
The luciferase experiments (Figure 7) suggest that on one
hand this sequence may serve as an enhancer, which could
cooperate with HIF for elevated transcription. The predomi-
nantly nuclear localization of the hypoxia-inducible hybrid
transcript may point also to a role in RNA stability. To date,
retained introns within several genes were found to enhance
almost every step of gene expression and also affects mRNA
stability. However, some studies showed that intron retention
has little or no effects on mRNA half-life,33–35 whereas others
confirmed that it is important for mRNA stability and has an
effect on prolonged mRNA half-life.36–38 In addition, cells
under hypoxia were even found to inhibit nonsense-mediated
RNA decay (NMD) mechanisms to enable the expression of
genes critical for cell adaptation and response to a cellular
stress.39 Moreover, many studies found that constitu-
tively spliced introns are required for optimal gene
expression,33,40,41 and one possible way through which
introns can affect transcription is by acting as repositories
for transcriptional regulatory elements such as enhancers and
repressors.41
Although further mechanistic studies as well as an under-
standing of the specific roles of the many transcripts at the
OGT locus are needed, this is the first study that purposely
investigates T-UCRs as a part of the hypoxic response and
extends the knowledge of the interplay between coding and
noncoding transcripts under stress conditions.
Materials and Methods
The complete version is included in the Supplementary Material.
Cell cultures and growth conditions. Colon cancer (HCT-116, HT-29
and COLO-205), breast cancer (MCF-7), bladder cancer (UC-2) and glioblastoma
(U-87) cell lines were obtained from ATCC (Manassas, VA, USA). RCC cell lines42
were obtained from Dr. Maria Czyzyk-Krzeska (University of Cincinnati, Cincinnati,
OH, USA). HCT-116 and HT-29 were maintained in McCoy’s 5A (enriched with
L-glutamine and sodium bicarbonate; Thermo Scientific, Logan, UT, USA); UC-2
was maintained in minimum essential Eagle medium (MEM; Cellgro Mediatech,
Manassas, VA, USA); MCF-7 was cultured in Dulbecco’s modified Eagle’s
Figure 5 Uc.475-transcript induction by hypoxia. Northern blot analysis of MCF-7 RNA identified transcripts of different sizes detected with uc.475 (left) or OGT probes
(right). Transcript variants identified by Northern blot signals in MCF-7 cells under normoxia and hypoxia are marked by arrows and visualized by a drawing (middle). The panel
PPIA was used as a loading control
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Figure 6 Impacts on OGT expression and function after uc.475 inhibition and O-GlcNAcylation change after knocking down uc.475 or OGT. (a) RT-qPCR expression
levels of OGT and uc.475 after uc.475 knockdown in HT-29 cells under normoxia and hypoxia. Primers were designed to detect both OGT1 and OGT2 isoforms. Error bars
indicate standard deviation. UCR or uc, ultraconserved gene; OGT, O-linked N-acetylglucosamine (GlcNAc) transferase; siRNA, small interfering RNA; HT-29, colon cancer
cell line; NOR, normoxia; HYP, hypoxia; PPIA, reference gene cyclophilin A; *P-valueo0.05, ***P-valueo0.001. (b) RT-qPCR confirmation of OGT gene knockdown using
siRNA against OGT. Primers specific for uc.475 and each of the OGT isoforms were used. (c) Western blot performed to detect differences of uc.475 host gene (OGT) protein
expression levels after OGT silencing. Hypoxic conditions were confirmed by CA9 induction. Protein-specific bands were normalized to beta-actin as a reference protein.
(d) O-GlcNAc protein levels were detected in samples exposed to hypoxic conditions for 72 h or simultaneously transfected with siRNA-targeting either uc.475, OGT
pre-mRNA or OGT. All levels were compared with sample transfected with siRNA-NEG. Different concentrations of PUGNAc were added in cell media (40 and 80 mM) to
prevent O-GlcNAc from being removed from the proteins. siRNA against OGT pre-mRNA was designed to target OGT-intron 12
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high-glucose medium (DMEM; Cellgro Mediatech); U-87 was cultured in special
DMEM supplemented with F12 50/50 mix (Cellgro Mediatech); COLO-205 was
maintained in RPMI 1640 (Cellgro Mediatech); and 786-O VEC (VHL  ) and
786-O WT (VHL þ )42 were cultured in DMEM : Ham’s F12 supplemented with
G418 (200mg/ml). All cell lines used were Mycoplasma-free, which was confirmed
by using the MycoAlert mycoplasma detection kit (Lonza, Rockland, ME, USA).
Before being used, cell lines were validated by STR DNA fingerprinting using the
AmpFcSTR Identifier kit, according to the manufacturer’s instructions (Applied
Biosystems, cat. no. 4322288). The STR profiles were compared with known ATCC
fingerprints (ATCC.org), the Cell Line Integrated Molecular Authentication database
version 0.1.200808 (http://bioinformatics.istge.it/clima/)43 and The University
of Texas MD Anderson Cancer Center fingerprint database. The STR profiles of
all the cell lines matched the known DNA fingerprints.
Clinical samples information is detailed in Supplementary Material.
Hypoxia experiments. Hypoxic experiments were performed in an InVivo2
200 hypoxia workstation (Ruskinn, Inc., Cincinnati, OH, USA), where oxygen
concentration was maintained at 1 or 0.2% (in 5% CO2 and 95% N2) for 24, 48, 72
and 96 h. RNA and proteins were collected for further analysis using RT-qPCR
and western blot, respectively.
Chemical induction of HIF-1a expression under normoxic conditions was
performed using DMOG (Frontier Scientific, Logan, UT, USA). DMOG was added to
the growth medium to a final concentration of 500mM versus of 0.5% DMSO vehicle
as control.
RNA extractions, RT-qPCR, real-time PCR controls and reference genes are
detailed in Supplementary Material.
Data analysis for RT-qPCR. Data analysis was performed using the Bio-
Rad CFX Manager Software (Bio-Rad, Hercules, CA, USA). Only samples with a
single clear peak in melting temperature and no expression in nontargeted control
cells were considered as positive and specific to be further analyzed. All RT-qPCR
data of expressed genes were represented as Cq values for each sample of
duplicates. Relative expression, as the fold change or difference,44 was calculated
using the 2(DDCq) formula, in which DCq represents the difference in Cq values
between the target gene and the mean Cq of the reference gene.
45 Each sample,
amplified using RT-qPCR, was tested in duplicate. Standard deviation (S.D.) of
each target gene was calculated.
Western blot analysis, siRNA transfection and FACS are detailed in
Supplementary Material.
HIF-1a-binding site predictions. We scanned the putative promoter
sequence ( 10 kb upstream and þ 10 kb downstream of the 50 end of
the annotated T-UCR) for predicted HIF-1a-binding sites generated using the
MATCH program and the V$HIF1_Q3 (50-gnnkACGTGcggnn-30), V$HIF1_Q5
(50-ngtACGTGcngb-30) and V$HIF1_Q6 (50-nRCGTGngn-30) position weight
matrices from the TRANSFAC database, version 9.146 (http://www.gene-
regulation.com). The position weight matrices describe the position preferences
of different nucleotides in the HIF-binding site.2
ChIP and the promoter reporter assays are detailed in Supplementary Material.
Detection of global O-GlcNAc cellular-protein modifications.
To detect O-GlcNAc-modified proteins, we chemically (PUGNAc as a
1,5-hydroximolactone is an inhibitor of various N-acetylhexosaminidases) prevented
the removal of O-GlcNAc modifications by the glycosidase MGEA5 (meningioma-
expressed antigen 5 (hyaluronidase)).47 PUGNAc treatment was initiated 24 h
after siRNA transfection. Fresh complete media containing PUGNAc was added to
final concentrations of 0, 40 and 80mM, respectively, and in duplicate wells. The
stock PUGNAc solution (SIGMA; cat. no. 132489-69-1) was prepared following the
manufacturer’s instructions and stored at  20 1C. After 72 h under normoxic or
hypoxic condition, cells were washed with phosphate-buffered saline (PBS) and
later harvested for RNA and protein extractions to determine siRNA knockdown
efficiency and to detect changes in O-GlcNAc, respectively. Primary and
mouse-specific secondary antibodies for detecting O-GlcNAc were reported by
Caldwell et al.22
ORF detection. OGT isoforms 1 and 2, and the retained intron sequence
(intron 4) of the OGT gene were all tested for ORF using the
NCBI ORF finder (http://www.ncbi.nlm.nih.gov/gorf/gorf.html).
Cell fractionation. Cells (HCT-116, 2 106) were pelleted, and cytoplasmic
and nuclear fractions were obtained using the PARIS kit following the
manufacturer’s protocol (Ambion RNA, Life Technologies, Carlsbad, CA, USA).
Oxygen and Glucose deprivation assays are described in Supplementary
Materials.
ncRNA array data analyses. Microarray chips were developed with a total
of 481 human UCR sequences as in http://www.soe.ucsc.edu/Bjill/ultra.html.
For each UCR, two 40-mer probes were designed, one corresponding to the sense
genomic sequence (named ‘þ ’) and the other to the complementary sequence
Figure 7 Testing the enhancer activity for cloned uc.475-containing region. Uc.475 enhancer activity experiments were performed in normoxia and hypoxia for 48 h.
(a) Insert representing a transcript of 2.7-kb region (including uc.475 region) was cloned downstream of the luciferase reporter. (b) Dual-Luciferase reporter assays were
performed on U-87 cell line samples exposed to normoxia or hypoxia for 48 h. x axis represents the relative Firefly to Renilla luciferase activity, whereas y axis presents the
plasmids. All measurements generated were normalized to the pGL3-TK empty vector. All data shown are the mean of two biological repetitions (at least eight luciferase
measurements per experiment). ***P-valueo0.001
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(named ‘Aþ ’). The design criteria were as described48 and the detailed array
description is in Calin et al.8 Images were quantified using the GenePix Pro 6.0
(Axon Instruments). Raw data were normalized and analyzed in GeneSpring
GX 7.3 (Agilent Technologies, Santa Clara, CA, USA). Tumors were normalized
using the on-chip and on-gene median normalization of the GeneSpring (Agilent
Technologies). Statistical comparisons of tumors and normal tissues were
performed by filtering on fold change and then by using the Welch t-test with
Benjamini–Hochberg correction for reduction of false-positives. All data were
submitted to the ArrayExpress database (accession number E-TABM-184).
Statistics. All results are based on at least two independent experimental
replicates, with error bars representing the standard error of the mean unless
stated otherwise. Unpaired two-tailed Student’s t-tests were used to address
differences between groups. Additionally, where indicated R-statistic was used
(version 2.14.2).
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